English

TAKEDA PHARMACEUTICAL CO LTD

EDGAR

TAK Report (type unavailable) · filed 2026-09-14

Annual consolidated revenue for 2026: about JPY 4.506T, using the latest reported figures. The previous period, 2025, was about JPY 4.582T.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

4.51 trillion JPY

2026 · JPY

Exact inputs and evidence

Revenue: 4505720000000 JPY Source

Operating margin

0.14%

2026 · %

Exact inputs and evidence

Operating Income: 6217000000 JPY Source
Revenue: 4505720000000 JPY Source

Operating cash flow

1.04 trillion JPY

2026 · JPY

Exact inputs and evidence

Operating Cash Flow: 1041431000000 JPY Source

Free cash flow

865 billion JPY

2026 · JPY

Exact inputs and evidence

Operating Cash Flow: 1041431000000 JPY Source
Capital Expenditure: 176003000000 JPY Source

Cash and cash equivalents: 595 billion JPY 2026-03-31 Source
Exact value

595054000000 JPY
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-14.

Financial data available through: 2026-03-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2026-03-31
Operating income: 10 of 11 periods available· newest 2026-03-31
Net income: 10 of 11 periods available· newest 2026-03-31
Operating cash flow: 10 of 11 periods available· newest 2026-03-31
Capital expenditure: 10 of 11 periods available· newest 2026-03-31
Total assets: 9 of 11 periods available· newest 2026-03-31
Total liabilities: 9 of 11 periods available· newest 2026-03-31
Current assets: 9 of 11 periods available· newest 2026-03-31
Current liabilities: 9 of 11 periods available· newest 2026-03-31
Cash and cash equivalents: 10 of 11 periods available· newest 2026-03-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-1.7%

Prior period

JPY 4.58 trillion

2024-04-01 – 2025-03-31
Current period

JPY 4.51 trillion

2025-04-01 – 2026-03-31

Exact inputs and evidence

4505720000000 − 4581551000000 = -75831000000 JPY

4581551000000 JPY · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
4505720000000 JPY · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · TAKEDA PHARMACEUTICAL CO LTD · 2026-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Year-over-year change in Revenue: -75831000000 JPY Concept: fundies:Revenue Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 4505720000000 JPY (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#3599606 Filing: 000139506426000177 Input fundies:Revenue: 4581551000000 JPY (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#3598755 Filing: 000139506426000177
The citation records this snapshot. The page link may show a newer release later.
Net income
-241.2%

Prior period

JPY 107.93 billion

2024-04-01 – 2025-03-31
Current period

−JPY 152.39 billion

2025-04-01 – 2026-03-31

Exact inputs and evidence

-152390000000 − 107928000000 = -260318000000 JPY

107928000000 JPY · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
-152390000000 JPY · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · TAKEDA PHARMACEUTICAL CO LTD · 2026-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Year-over-year change in Net income: -260318000000 JPY Concept: fundies:NetIncome Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -152390000000 JPY (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#3631257 Filing: 000139506426000177 Input fundies:NetIncome: 107928000000 JPY (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#3630462 Filing: 000139506426000177
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-1.5%

Prior period

JPY 1.06 trillion

2024-04-01 – 2025-03-31
Current period

JPY 1.04 trillion

2025-04-01 – 2026-03-31

Exact inputs and evidence

1041431000000 − 1057182000000 = -15751000000 JPY

1057182000000 JPY · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
1041431000000 JPY · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · TAKEDA PHARMACEUTICAL CO LTD · 2026-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Year-over-year change in Operating cash flow: -15751000000 JPY Concept: fundies:OperatingCashFlow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 1041431000000 JPY (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4156465 Filing: 000139506426000177 Input fundies:OperatingCashFlow: 1057182000000 JPY (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4155814 Filing: 000139506426000177
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-12.3%

Prior period

JPY 200.8 billion

2024-04-01 – 2025-03-31
Current period

JPY 176 billion

2025-04-01 – 2026-03-31

Exact inputs and evidence

176003000000 − 200795000000 = -24792000000 JPY

200795000000 JPY · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
176003000000 JPY · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · TAKEDA PHARMACEUTICAL CO LTD · 2026-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Year-over-year change in Capital expenditure: -24792000000 JPY Concept: fundies:CapitalExpenditure Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 176003000000 JPY (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4163427 Filing: 000139506426000177 Input fundies:CapitalExpenditure: 200795000000 JPY (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4162812 Filing: 000139506426000177
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2026 2025-04-01 – 2026-03-31

Revenue JPY 4.51 trillion 100% of revenue
Operating costs Derived JPY 4.5 trillion 100% of revenue
Operating income JPY 6.22 billion 0.1% of revenue
Tax, interest and other Derived JPY 158.61 billion 3.5% of revenue
Net income −JPY 152.39 billion −3.4% of revenue

Cash

Operating cash flow JPY 1.04 trillion 23% of revenue
Capital expenditure JPY 176 billion 3.9% of revenue
Free cash flow Derived JPY 865.43 billion 19% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 91%
2018 11%86%
2019 89%
2020 97%
2021 12%84%
2022 87%
2023 88%
2024 95%
2025 93%
2026 Net loss: net income was −3.4% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2016-04-01 – 2017-03-31	1732051000000	1576184000000 Derived	155867000000	40927000000 Derived	114940000000	199703000000 Derived	Source 2016-04-01 – 2017-03-31: 1732051000000 JPY Inspect Revenue Open source 2016-04-01 – 2017-03-31: 155867000000 JPY Inspect Operating Income Open source 2016-04-01 – 2017-03-31: 114940000000 JPY Inspect Net Income Open source 2016-04-01 – 2017-03-31: 261363000000 JPY Inspect Operating Cash Flow Open source 2016-04-01 – 2017-03-31: 61660000000 JPY Inspect Capital Expenditure Open source
2018 2017-04-01 – 2018-03-31	1770531000000	1528742000000 Derived	241789000000	54903000000 Derived	186886000000	310849000000 Derived	Source 2017-04-01 – 2018-03-31: 1770531000000 JPY Inspect Revenue Open source 2017-04-01 – 2018-03-31: 241789000000 JPY Inspect Operating Income Open source 2017-04-01 – 2018-03-31: 186886000000 JPY Inspect Net Income Open source 2017-04-01 – 2018-03-31: 377854000000 JPY Inspect Operating Cash Flow Open source 2017-04-01 – 2018-03-31: 67005000000 JPY Inspect Capital Expenditure Open source
2019 2018-04-01 – 2019-03-31	2097224000000	1859539000000 Derived	237685000000	102493000000 Derived	135192000000	250802000000 Derived	Source 2018-04-01 – 2019-03-31: 2097224000000 JPY Inspect Revenue Open source 2018-04-01 – 2019-03-31: 237685000000 JPY Inspect Operating Income Open source 2018-04-01 – 2019-03-31: 135192000000 JPY Inspect Net Income Open source 2018-04-01 – 2019-03-31: 328479000000 JPY Inspect Operating Cash Flow Open source 2018-04-01 – 2019-03-31: 77677000000 JPY Inspect Capital Expenditure Open source
2020 2019-04-01 – 2020-03-31	3291188000000	3190780000000 Derived	100408000000	56167000000 Derived	44241000000	542670000000 Derived	Source 2019-04-01 – 2020-03-31: 3291188000000 JPY Inspect Revenue Open source 2019-04-01 – 2020-03-31: 100408000000 JPY Inspect Operating Income Open source 2019-04-01 – 2020-03-31: 44241000000 JPY Inspect Net Income Open source 2019-04-01 – 2020-03-31: 669752000000 JPY Inspect Operating Cash Flow Open source 2019-04-01 – 2020-03-31: 127082000000 JPY Inspect Capital Expenditure Open source
2021 2020-04-01 – 2021-03-31	3197812000000	2688543000000 Derived	509269000000	133264000000 Derived	376005000000	899725000000 Derived	Source 2020-04-01 – 2021-03-31: 3197812000000 JPY Inspect Revenue Open source 2020-04-01 – 2021-03-31: 509269000000 JPY Inspect Operating Income Open source 2020-04-01 – 2021-03-31: 376005000000 JPY Inspect Net Income Open source 2020-04-01 – 2021-03-31: 1010931000000 JPY Inspect Operating Cash Flow Open source 2020-04-01 – 2021-03-31: 111206000000 JPY Inspect Capital Expenditure Open source
2022 2021-04-01 – 2022-03-31	3569006000000	3108162000000 Derived	460844000000	230785000000 Derived	230059000000	999853000000 Derived	Source 2021-04-01 – 2022-03-31: 3569006000000 JPY Inspect Revenue Open source 2021-04-01 – 2022-03-31: 460844000000 JPY Inspect Operating Income Open source 2021-04-01 – 2022-03-31: 230059000000 JPY Inspect Net Income Open source 2021-04-01 – 2022-03-31: 1123105000000 JPY Inspect Operating Cash Flow Open source 2021-04-01 – 2022-03-31: 123252000000 JPY Inspect Capital Expenditure Open source
2023 2022-04-01 – 2023-03-31	4027478000000	3536973000000 Derived	490505000000	173488000000 Derived	317017000000	836499000000 Derived	Source 2022-04-01 – 2023-03-31: 4027478000000 JPY Inspect Revenue Open source 2022-04-01 – 2023-03-31: 490505000000 JPY Inspect Operating Income Open source 2022-04-01 – 2023-03-31: 317017000000 JPY Inspect Net Income Open source 2022-04-01 – 2023-03-31: 977156000000 JPY Inspect Operating Cash Flow Open source 2022-04-01 – 2023-03-31: 140657000000 JPY Inspect Capital Expenditure Open source
2024 2023-04-01 – 2024-03-31	4263762000000	4049687000000 Derived	214075000000	70008000000 Derived	144067000000	540924000000 Derived	Source 2023-04-01 – 2024-03-31: 4263762000000 JPY Inspect Revenue Open source 2023-04-01 – 2024-03-31: 214075000000 JPY Inspect Operating Income Open source 2023-04-01 – 2024-03-31: 144067000000 JPY Inspect Net Income Open source 2023-04-01 – 2024-03-31: 716344000000 JPY Inspect Operating Cash Flow Open source 2023-04-01 – 2024-03-31: 175420000000 JPY Inspect Capital Expenditure Open source
2025 2024-04-01 – 2025-03-31	4581551000000	4238965000000 Derived	342586000000	234658000000 Derived	107928000000	856387000000 Derived	Source 2024-04-01 – 2025-03-31: 4581551000000 JPY Inspect Revenue Open source 2024-04-01 – 2025-03-31: 342586000000 JPY Inspect Operating Income Open source 2024-04-01 – 2025-03-31: 107928000000 JPY Inspect Net Income Open source 2024-04-01 – 2025-03-31: 1057182000000 JPY Inspect Operating Cash Flow Open source 2024-04-01 – 2025-03-31: 200795000000 JPY Inspect Capital Expenditure Open source
2026 2025-04-01 – 2026-03-31	4505720000000	4499503000000 Derived	6217000000	158607000000 Derived	-152390000000	865428000000 Derived	Source 2025-04-01 – 2026-03-31: 4505720000000 JPY Inspect Revenue Open source 2025-04-01 – 2026-03-31: 6217000000 JPY Inspect Operating Income Open source 2025-04-01 – 2026-03-31: -152390000000 JPY Inspect Net Income Open source 2025-04-01 – 2026-03-31: 1041431000000 JPY Inspect Operating Cash Flow Open source 2025-04-01 – 2026-03-31: 176003000000 JPY Inspect Capital Expenditure Open source

Amounts are exact, in JPY.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

JPY 4.5T 2026

Values and sources

Revenue values and source evidence
Period	Series	Value(JPY)	Source evidence
20172017-03-31	Revenue	1732051000000	Revenue: 1732051000000 Open source
20182018-03-31	Revenue	1770531000000	Revenue: 1770531000000 Open source
20192019-03-31	Revenue	2097224000000	Revenue: 2097224000000 Open source
20202020-03-31	Revenue	3291188000000	Revenue: 3291188000000 Open source
20212021-03-31	Revenue	3197812000000	Revenue: 3197812000000 Open source
20222022-03-31	Revenue	3569006000000	Revenue: 3569006000000 Open source
20232023-03-31	Revenue	4027478000000	Revenue: 4027478000000 Open source
20242024-03-31	Revenue	4263762000000	Revenue: 4263762000000 Open source
20252025-03-31	Revenue	4581551000000	Revenue: 4581551000000 Open source
20262026-03-31	Revenue	4505720000000	Revenue: 4505720000000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-1.7% 2026

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Year over year	No prior comparable period	Revenue: 1732051000000 Open source
20182018-03-31	Year over year	2.2%	Revenue: 1770531000000 Open source Revenue: 1732051000000 Open source
20192019-03-31	Year over year	18.5%	Revenue: 2097224000000 Open source Revenue: 1770531000000 Open source
20202020-03-31	Year over year	56.9%	Revenue: 3291188000000 Open source Revenue: 2097224000000 Open source
20212021-03-31	Year over year	-2.8%	Revenue: 3197812000000 Open source Revenue: 3291188000000 Open source
20222022-03-31	Year over year	11.6%	Revenue: 3569006000000 Open source Revenue: 3197812000000 Open source
20232023-03-31	Year over year	12.8%	Revenue: 4027478000000 Open source Revenue: 3569006000000 Open source
20242024-03-31	Year over year	5.9%	Revenue: 4263762000000 Open source Revenue: 4027478000000 Open source
20252025-03-31	Year over year	7.5%	Revenue: 4581551000000 Open source Revenue: 4263762000000 Open source
20262026-03-31	Year over year	-1.7%	Revenue: 4505720000000 Open source Revenue: 4581551000000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 0.1% 2026

Net margin -3.4% 2026

Free cash flow margin 19.2% 2026

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Operating margin	9%	Operating Income: 155867000000 Open source Revenue: 1732051000000 Open source
20182018-03-31	Operating margin	13.7%	Operating Income: 241789000000 Open source Revenue: 1770531000000 Open source
20192019-03-31	Operating margin	11.3%	Operating Income: 237685000000 Open source Revenue: 2097224000000 Open source
20202020-03-31	Operating margin	3.1%	Operating Income: 100408000000 Open source Revenue: 3291188000000 Open source
20212021-03-31	Operating margin	15.9%	Operating Income: 509269000000 Open source Revenue: 3197812000000 Open source
20222022-03-31	Operating margin	12.9%	Operating Income: 460844000000 Open source Revenue: 3569006000000 Open source
20232023-03-31	Operating margin	12.2%	Operating Income: 490505000000 Open source Revenue: 4027478000000 Open source
20242024-03-31	Operating margin	5%	Operating Income: 214075000000 Open source Revenue: 4263762000000 Open source
20252025-03-31	Operating margin	7.5%	Operating Income: 342586000000 Open source Revenue: 4581551000000 Open source
20262026-03-31	Operating margin	0.1%	Operating Income: 6217000000 Open source Revenue: 4505720000000 Open source
20172017-03-31	Net margin	6.6%	Net Income: 114940000000 Open source Revenue: 1732051000000 Open source
20182018-03-31	Net margin	10.6%	Net Income: 186886000000 Open source Revenue: 1770531000000 Open source
20192019-03-31	Net margin	6.4%	Net Income: 135192000000 Open source Revenue: 2097224000000 Open source
20202020-03-31	Net margin	1.3%	Net Income: 44241000000 Open source Revenue: 3291188000000 Open source
20212021-03-31	Net margin	11.8%	Net Income: 376005000000 Open source Revenue: 3197812000000 Open source
20222022-03-31	Net margin	6.4%	Net Income: 230059000000 Open source Revenue: 3569006000000 Open source
20232023-03-31	Net margin	7.9%	Net Income: 317017000000 Open source Revenue: 4027478000000 Open source
20242024-03-31	Net margin	3.4%	Net Income: 144067000000 Open source Revenue: 4263762000000 Open source
20252025-03-31	Net margin	2.4%	Net Income: 107928000000 Open source Revenue: 4581551000000 Open source
20262026-03-31	Net margin	-3.4%	Net Income: -152390000000 Open source Revenue: 4505720000000 Open source
20172017-03-31	Free cash flow margin	11.5%	Revenue: 1732051000000 Open source Operating Cash Flow: 261363000000 Open source Capital Expenditure: 61660000000 Open source
20182018-03-31	Free cash flow margin	17.6%	Revenue: 1770531000000 Open source Operating Cash Flow: 377854000000 Open source Capital Expenditure: 67005000000 Open source
20192019-03-31	Free cash flow margin	12%	Revenue: 2097224000000 Open source Operating Cash Flow: 328479000000 Open source Capital Expenditure: 77677000000 Open source
20202020-03-31	Free cash flow margin	16.5%	Revenue: 3291188000000 Open source Operating Cash Flow: 669752000000 Open source Capital Expenditure: 127082000000 Open source
20212021-03-31	Free cash flow margin	28.1%	Revenue: 3197812000000 Open source Operating Cash Flow: 1010931000000 Open source Capital Expenditure: 111206000000 Open source
20222022-03-31	Free cash flow margin	28%	Revenue: 3569006000000 Open source Operating Cash Flow: 1123105000000 Open source Capital Expenditure: 123252000000 Open source
20232023-03-31	Free cash flow margin	20.8%	Revenue: 4027478000000 Open source Operating Cash Flow: 977156000000 Open source Capital Expenditure: 140657000000 Open source
20242024-03-31	Free cash flow margin	12.7%	Revenue: 4263762000000 Open source Operating Cash Flow: 716344000000 Open source Capital Expenditure: 175420000000 Open source
20252025-03-31	Free cash flow margin	18.7%	Revenue: 4581551000000 Open source Operating Cash Flow: 1057182000000 Open source Capital Expenditure: 200795000000 Open source
20262026-03-31	Free cash flow margin	19.2%	Revenue: 4505720000000 Open source Operating Cash Flow: 1041431000000 Open source Capital Expenditure: 176003000000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

JPY 1T 2026

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(JPY)	Source evidence
20172017-03-31	Operating cash flow	261363000000	Operating Cash Flow: 261363000000 Open source
20182018-03-31	Operating cash flow	377854000000	Operating Cash Flow: 377854000000 Open source
20192019-03-31	Operating cash flow	328479000000	Operating Cash Flow: 328479000000 Open source
20202020-03-31	Operating cash flow	669752000000	Operating Cash Flow: 669752000000 Open source
20212021-03-31	Operating cash flow	1010931000000	Operating Cash Flow: 1010931000000 Open source
20222022-03-31	Operating cash flow	1123105000000	Operating Cash Flow: 1123105000000 Open source
20232023-03-31	Operating cash flow	977156000000	Operating Cash Flow: 977156000000 Open source
20242024-03-31	Operating cash flow	716344000000	Operating Cash Flow: 716344000000 Open source
20252025-03-31	Operating cash flow	1057182000000	Operating Cash Flow: 1057182000000 Open source
20262026-03-31	Operating cash flow	1041431000000	Operating Cash Flow: 1041431000000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

JPY 865.4B 2026

Values and sources

Free cash flow values and source evidence
Period	Series	Value(JPY)	Source evidence
20172017-03-31	Free cash flow	199703000000	Operating Cash Flow: 261363000000 Open source Capital Expenditure: 61660000000 Open source
20182018-03-31	Free cash flow	310849000000	Operating Cash Flow: 377854000000 Open source Capital Expenditure: 67005000000 Open source
20192019-03-31	Free cash flow	250802000000	Operating Cash Flow: 328479000000 Open source Capital Expenditure: 77677000000 Open source
20202020-03-31	Free cash flow	542670000000	Operating Cash Flow: 669752000000 Open source Capital Expenditure: 127082000000 Open source
20212021-03-31	Free cash flow	899725000000	Operating Cash Flow: 1010931000000 Open source Capital Expenditure: 111206000000 Open source
20222022-03-31	Free cash flow	999853000000	Operating Cash Flow: 1123105000000 Open source Capital Expenditure: 123252000000 Open source
20232023-03-31	Free cash flow	836499000000	Operating Cash Flow: 977156000000 Open source Capital Expenditure: 140657000000 Open source
20242024-03-31	Free cash flow	540924000000	Operating Cash Flow: 716344000000 Open source Capital Expenditure: 175420000000 Open source
20252025-03-31	Free cash flow	856387000000	Operating Cash Flow: 1057182000000 Open source Capital Expenditure: 200795000000 Open source
20262026-03-31	Free cash flow	865428000000	Operating Cash Flow: 1041431000000 Open source Capital Expenditure: 176003000000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

52.1% 2026

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2017-03-31	Liabilities / assets	Not reported	No source recorded
20182018-03-31	Liabilities / assets	50.9%	Total Liabilities: 2089054000000 Open source Total Assets: 4106463000000 Open source
20192019-03-31	Liabilities / assets	62.4%	Total Liabilities: 8606782000000 Open source Total Assets: 13792773000000 Open source
20202020-03-31	Liabilities / assets	63.1%	Total Liabilities: 8093608000000 Open source Total Assets: 12821094000000 Open source
20212021-03-31	Liabilities / assets	59.9%	Total Liabilities: 7735116000000 Open source Total Assets: 12912293000000 Open source
20222022-03-31	Liabilities / assets	56.9%	Total Liabilities: 7494495000000 Open source Total Assets: 13178018000000 Open source
20232023-03-31	Liabilities / assets	54.5%	Total Liabilities: 7603078000000 Open source Total Assets: 13957750000000 Open source
20242024-03-31	Liabilities / assets	51.9%	Total Liabilities: 7834788000000 Open source Total Assets: 15108792000000 Open source
20252025-03-31	Liabilities / assets	51.3%	Total Liabilities: 7312365000000 Open source Total Assets: 14248344000000 Open source
20262026-03-31	Liabilities / assets	52.1%	Total Liabilities: 8080858000000 Open source Total Assets: 15511506000000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.09× 2026

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2017-03-31	Current assets / current liabilities	Not reported	No source recorded
20182018-03-31	Current assets / current liabilities	1.46×	Current Assets: 1078808000000 Open source Current Liabilities: 737509000000 Open source
20192019-03-31	Current assets / current liabilities	1.17×	Current Assets: 2993037000000 Open source Current Liabilities: 2553049000000 Open source
20202020-03-31	Current assets / current liabilities	1.13×	Current Assets: 2469432000000 Open source Current Liabilities: 2175898000000 Open source
20212021-03-31	Current assets / current liabilities	1.53×	Current Assets: 2712893000000 Open source Current Liabilities: 1773176000000 Open source
20222022-03-31	Current assets / current liabilities	1.21×	Current Assets: 2593642000000 Open source Current Liabilities: 2145730000000 Open source
20232023-03-31	Current assets / current liabilities	0.97×	Current Assets: 2397956000000 Open source Current Liabilities: 2481940000000 Open source
20242024-03-31	Current assets / current liabilities	1.11×	Current Assets: 2558580000000 Open source Current Liabilities: 2313103000000 Open source
20252025-03-31	Current assets / current liabilities	1.01×	Current Assets: 2521192000000 Open source Current Liabilities: 2506521000000 Open source
20262026-03-31	Current assets / current liabilities	1.09×	Current Assets: 3090503000000 Open source Current Liabilities: 2832074000000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2016-04-01 – 2017-03-31	JPY 114.94 billion Exact value Exact value: 114940000000 JPY 2016-04-01 – 2017-03-31: 114940000000 JPY Inspect Net Income Open source Share or cite Citation for Net Income · TAKEDA PHARMACEUTICAL CO LTD · 2017-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Net Income: 114940000000 JPY Concept: fundies:NetIncome Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ANetIncome&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=JPY&dimensions= Input fundies:NetIncome: 114940000000 JPY (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506419000005/tak-20190331.xml#1460785 Filing: 000139506419000005 The citation records this snapshot. The page link may show a newer release later.	JPY 261.36 billion Exact value Exact value: 261363000000 JPY 2016-04-01 – 2017-03-31: 261363000000 JPY Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TAKEDA PHARMACEUTICAL CO LTD · 2017-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Operating Cash Flow: 261363000000 JPY Concept: fundies:OperatingCashFlow Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3AOperatingCashFlow&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=JPY&dimensions= Input fundies:OperatingCashFlow: 261363000000 JPY (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506419000005/tak-20190331.xml#908906 Filing: 000139506419000005 The citation records this snapshot. The page link may show a newer release later.	JPY 61.66 billion Exact value Exact value: 61660000000 JPY 2016-04-01 – 2017-03-31: 61660000000 JPY Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TAKEDA PHARMACEUTICAL CO LTD · 2017-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Capital Expenditure: 61660000000 JPY Concept: fundies:CapitalExpenditure Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ACapitalExpenditure&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=JPY&dimensions= Input fundies:CapitalExpenditure: 61660000000 JPY (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506419000005/tak-20190331.xml#1512177 Filing: 000139506419000005 The citation records this snapshot. The page link may show a newer release later.	JPY 199.7 billion Calculation and evidence 261363000000 − 61660000000 JPY Exact free cash flow: 199703000000 JPY 2016-04-01 – 2017-03-31: 261363000000 JPY · Inspect Operating Cash Flow · Source 2016-04-01 – 2017-03-31: 61660000000 JPY · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TAKEDA PHARMACEUTICAL CO LTD · 2017-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Free cash flow: 199703000000 JPY Concept: free-cash-flow Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 261363000000 JPY (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506419000005/tak-20190331.xml#908906 Filing: 000139506419000005 Input fundies:CapitalExpenditure: 61660000000 JPY (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506419000005/tak-20190331.xml#1512177 Filing: 000139506419000005 The citation records this snapshot. The page link may show a newer release later.
2018 2017-04-01 – 2018-03-31	JPY 186.89 billion Exact value Exact value: 186886000000 JPY 2017-04-01 – 2018-03-31: 186886000000 JPY Inspect Net Income Open source Share or cite Citation for Net Income · TAKEDA PHARMACEUTICAL CO LTD · 2018-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Net Income: 186886000000 JPY Concept: fundies:NetIncome Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ANetIncome&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=JPY&dimensions= Input fundies:NetIncome: 186886000000 JPY (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506420000110/tak-20200331.xml#1666882 Filing: 000139506420000110 The citation records this snapshot. The page link may show a newer release later.	JPY 377.85 billion Exact value Exact value: 377854000000 JPY 2017-04-01 – 2018-03-31: 377854000000 JPY Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TAKEDA PHARMACEUTICAL CO LTD · 2018-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Operating Cash Flow: 377854000000 JPY Concept: fundies:OperatingCashFlow Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3AOperatingCashFlow&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=JPY&dimensions= Input fundies:OperatingCashFlow: 377854000000 JPY (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506420000110/tak-20200331.xml#1069974 Filing: 000139506420000110 The citation records this snapshot. The page link may show a newer release later.	JPY 67.01 billion Exact value Exact value: 67005000000 JPY 2017-04-01 – 2018-03-31: 67005000000 JPY Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TAKEDA PHARMACEUTICAL CO LTD · 2018-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Capital Expenditure: 67005000000 JPY Concept: fundies:CapitalExpenditure Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ACapitalExpenditure&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=JPY&dimensions= Input fundies:CapitalExpenditure: 67005000000 JPY (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506420000110/tak-20200331.xml#1724317 Filing: 000139506420000110 The citation records this snapshot. The page link may show a newer release later.	JPY 310.85 billion Calculation and evidence 377854000000 − 67005000000 JPY Exact free cash flow: 310849000000 JPY 2017-04-01 – 2018-03-31: 377854000000 JPY · Inspect Operating Cash Flow · Source 2017-04-01 – 2018-03-31: 67005000000 JPY · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TAKEDA PHARMACEUTICAL CO LTD · 2018-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Free cash flow: 310849000000 JPY Concept: free-cash-flow Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 377854000000 JPY (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506420000110/tak-20200331.xml#1069974 Filing: 000139506420000110 Input fundies:CapitalExpenditure: 67005000000 JPY (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506420000110/tak-20200331.xml#1724317 Filing: 000139506420000110 The citation records this snapshot. The page link may show a newer release later.
2019 2018-04-01 – 2019-03-31	JPY 135.19 billion Exact value Exact value: 135192000000 JPY 2018-04-01 – 2019-03-31: 135192000000 JPY Inspect Net Income Open source Share or cite Citation for Net Income · TAKEDA PHARMACEUTICAL CO LTD · 2019-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Net Income: 135192000000 JPY Concept: fundies:NetIncome Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ANetIncome&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=JPY&dimensions= Input fundies:NetIncome: 135192000000 JPY (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506421000140/tak-20210331.htm#2958817 Filing: 000139506421000140 The citation records this snapshot. The page link may show a newer release later.	JPY 328.48 billion Exact value Exact value: 328479000000 JPY 2018-04-01 – 2019-03-31: 328479000000 JPY Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TAKEDA PHARMACEUTICAL CO LTD · 2019-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Operating Cash Flow: 328479000000 JPY Concept: fundies:OperatingCashFlow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3AOperatingCashFlow&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=JPY&dimensions= Input fundies:OperatingCashFlow: 328479000000 JPY (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506421000140/tak-20210331.htm#3687480 Filing: 000139506421000140 The citation records this snapshot. The page link may show a newer release later.	JPY 77.68 billion Exact value Exact value: 77677000000 JPY 2018-04-01 – 2019-03-31: 77677000000 JPY Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TAKEDA PHARMACEUTICAL CO LTD · 2019-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Capital Expenditure: 77677000000 JPY Concept: fundies:CapitalExpenditure Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ACapitalExpenditure&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=JPY&dimensions= Input fundies:CapitalExpenditure: 77677000000 JPY (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506421000140/tak-20210331.htm#3698114 Filing: 000139506421000140 The citation records this snapshot. The page link may show a newer release later.	JPY 250.8 billion Calculation and evidence 328479000000 − 77677000000 JPY Exact free cash flow: 250802000000 JPY 2018-04-01 – 2019-03-31: 328479000000 JPY · Inspect Operating Cash Flow · Source 2018-04-01 – 2019-03-31: 77677000000 JPY · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TAKEDA PHARMACEUTICAL CO LTD · 2019-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Free cash flow: 250802000000 JPY Concept: free-cash-flow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 328479000000 JPY (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506421000140/tak-20210331.htm#3687480 Filing: 000139506421000140 Input fundies:CapitalExpenditure: 77677000000 JPY (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506421000140/tak-20210331.htm#3698114 Filing: 000139506421000140 The citation records this snapshot. The page link may show a newer release later.
2020 2019-04-01 – 2020-03-31	JPY 44.24 billion Exact value Exact value: 44241000000 JPY 2019-04-01 – 2020-03-31: 44241000000 JPY Inspect Net Income Open source Share or cite Citation for Net Income · TAKEDA PHARMACEUTICAL CO LTD · 2020-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Net Income: 44241000000 JPY Concept: fundies:NetIncome Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ANetIncome&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=JPY&dimensions= Input fundies:NetIncome: 44241000000 JPY (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506422000107/tak-20220331.htm#2966488 Filing: 000139506422000107 The citation records this snapshot. The page link may show a newer release later.	JPY 669.75 billion Exact value Exact value: 669752000000 JPY 2019-04-01 – 2020-03-31: 669752000000 JPY Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TAKEDA PHARMACEUTICAL CO LTD · 2020-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Operating Cash Flow: 669752000000 JPY Concept: fundies:OperatingCashFlow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3AOperatingCashFlow&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=JPY&dimensions= Input fundies:OperatingCashFlow: 669752000000 JPY (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506422000107/tak-20220331.htm#3652800 Filing: 000139506422000107 The citation records this snapshot. The page link may show a newer release later.	JPY 127.08 billion Exact value Exact value: 127082000000 JPY 2019-04-01 – 2020-03-31: 127082000000 JPY Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TAKEDA PHARMACEUTICAL CO LTD · 2020-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Capital Expenditure: 127082000000 JPY Concept: fundies:CapitalExpenditure Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ACapitalExpenditure&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=JPY&dimensions= Input fundies:CapitalExpenditure: 127082000000 JPY (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506422000107/tak-20220331.htm#3663515 Filing: 000139506422000107 The citation records this snapshot. The page link may show a newer release later.	JPY 542.67 billion Calculation and evidence 669752000000 − 127082000000 JPY Exact free cash flow: 542670000000 JPY 2019-04-01 – 2020-03-31: 669752000000 JPY · Inspect Operating Cash Flow · Source 2019-04-01 – 2020-03-31: 127082000000 JPY · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TAKEDA PHARMACEUTICAL CO LTD · 2020-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Free cash flow: 542670000000 JPY Concept: free-cash-flow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 669752000000 JPY (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506422000107/tak-20220331.htm#3652800 Filing: 000139506422000107 Input fundies:CapitalExpenditure: 127082000000 JPY (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506422000107/tak-20220331.htm#3663515 Filing: 000139506422000107 The citation records this snapshot. The page link may show a newer release later.
2021 2020-04-01 – 2021-03-31	JPY 376.01 billion Exact value Exact value: 376005000000 JPY 2020-04-01 – 2021-03-31: 376005000000 JPY Inspect Net Income Open source Share or cite Citation for Net Income · TAKEDA PHARMACEUTICAL CO LTD · 2021-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Net Income: 376005000000 JPY Concept: fundies:NetIncome Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ANetIncome&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=JPY&dimensions= Input fundies:NetIncome: 376005000000 JPY (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506423000072/tak-20230331.htm#2926799 Filing: 000139506423000072 The citation records this snapshot. The page link may show a newer release later.	JPY 1.01 trillion Exact value Exact value: 1010931000000 JPY 2020-04-01 – 2021-03-31: 1010931000000 JPY Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TAKEDA PHARMACEUTICAL CO LTD · 2021-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Operating Cash Flow: 1010931000000 JPY Concept: fundies:OperatingCashFlow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3AOperatingCashFlow&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=JPY&dimensions= Input fundies:OperatingCashFlow: 1010931000000 JPY (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506423000072/tak-20230331.htm#3441414 Filing: 000139506423000072 The citation records this snapshot. The page link may show a newer release later.	JPY 111.21 billion Exact value Exact value: 111206000000 JPY 2020-04-01 – 2021-03-31: 111206000000 JPY Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TAKEDA PHARMACEUTICAL CO LTD · 2021-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Capital Expenditure: 111206000000 JPY Concept: fundies:CapitalExpenditure Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ACapitalExpenditure&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=JPY&dimensions= Input fundies:CapitalExpenditure: 111206000000 JPY (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506423000072/tak-20230331.htm#3449077 Filing: 000139506423000072 The citation records this snapshot. The page link may show a newer release later.	JPY 899.73 billion Calculation and evidence 1010931000000 − 111206000000 JPY Exact free cash flow: 899725000000 JPY 2020-04-01 – 2021-03-31: 1010931000000 JPY · Inspect Operating Cash Flow · Source 2020-04-01 – 2021-03-31: 111206000000 JPY · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TAKEDA PHARMACEUTICAL CO LTD · 2021-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Free cash flow: 899725000000 JPY Concept: free-cash-flow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1010931000000 JPY (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506423000072/tak-20230331.htm#3441414 Filing: 000139506423000072 Input fundies:CapitalExpenditure: 111206000000 JPY (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506423000072/tak-20230331.htm#3449077 Filing: 000139506423000072 The citation records this snapshot. The page link may show a newer release later.
2022 2021-04-01 – 2022-03-31	JPY 230.06 billion Exact value Exact value: 230059000000 JPY 2021-04-01 – 2022-03-31: 230059000000 JPY Inspect Net Income Open source Share or cite Citation for Net Income · TAKEDA PHARMACEUTICAL CO LTD · 2022-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Net Income: 230059000000 JPY Concept: fundies:NetIncome Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ANetIncome&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=JPY&dimensions= Input fundies:NetIncome: 230059000000 JPY (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506424000086/tak-20240331.htm#3626768 Filing: 000139506424000086 The citation records this snapshot. The page link may show a newer release later.	JPY 1.12 trillion Exact value Exact value: 1123105000000 JPY 2021-04-01 – 2022-03-31: 1123105000000 JPY Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TAKEDA PHARMACEUTICAL CO LTD · 2022-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Operating Cash Flow: 1123105000000 JPY Concept: fundies:OperatingCashFlow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3AOperatingCashFlow&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=JPY&dimensions= Input fundies:OperatingCashFlow: 1123105000000 JPY (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506424000086/tak-20240331.htm#4108904 Filing: 000139506424000086 The citation records this snapshot. The page link may show a newer release later.	JPY 123.25 billion Exact value Exact value: 123252000000 JPY 2021-04-01 – 2022-03-31: 123252000000 JPY Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TAKEDA PHARMACEUTICAL CO LTD · 2022-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Capital Expenditure: 123252000000 JPY Concept: fundies:CapitalExpenditure Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ACapitalExpenditure&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=JPY&dimensions= Input fundies:CapitalExpenditure: 123252000000 JPY (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506424000086/tak-20240331.htm#4116067 Filing: 000139506424000086 The citation records this snapshot. The page link may show a newer release later.	JPY 999.85 billion Calculation and evidence 1123105000000 − 123252000000 JPY Exact free cash flow: 999853000000 JPY 2021-04-01 – 2022-03-31: 1123105000000 JPY · Inspect Operating Cash Flow · Source 2021-04-01 – 2022-03-31: 123252000000 JPY · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TAKEDA PHARMACEUTICAL CO LTD · 2022-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Free cash flow: 999853000000 JPY Concept: free-cash-flow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1123105000000 JPY (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506424000086/tak-20240331.htm#4108904 Filing: 000139506424000086 Input fundies:CapitalExpenditure: 123252000000 JPY (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506424000086/tak-20240331.htm#4116067 Filing: 000139506424000086 The citation records this snapshot. The page link may show a newer release later.
2023 2022-04-01 – 2023-03-31	JPY 317.02 billion Exact value Exact value: 317017000000 JPY 2022-04-01 – 2023-03-31: 317017000000 JPY Inspect Net Income Open source Share or cite Citation for Net Income · TAKEDA PHARMACEUTICAL CO LTD · 2023-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Net Income: 317017000000 JPY Concept: fundies:NetIncome Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ANetIncome&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=JPY&dimensions= Input fundies:NetIncome: 317017000000 JPY (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506425000095/tak-20250331.htm#3690936 Filing: 000139506425000095 The citation records this snapshot. The page link may show a newer release later.	JPY 977.16 billion Exact value Exact value: 977156000000 JPY 2022-04-01 – 2023-03-31: 977156000000 JPY Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TAKEDA PHARMACEUTICAL CO LTD · 2023-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Operating Cash Flow: 977156000000 JPY Concept: fundies:OperatingCashFlow Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3AOperatingCashFlow&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=JPY&dimensions= Input fundies:OperatingCashFlow: 977156000000 JPY (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506425000095/tak-20250331.htm#4213204 Filing: 000139506425000095 The citation records this snapshot. The page link may show a newer release later.	JPY 140.66 billion Exact value Exact value: 140657000000 JPY 2022-04-01 – 2023-03-31: 140657000000 JPY Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TAKEDA PHARMACEUTICAL CO LTD · 2023-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Capital Expenditure: 140657000000 JPY Concept: fundies:CapitalExpenditure Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ACapitalExpenditure&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=JPY&dimensions= Input fundies:CapitalExpenditure: 140657000000 JPY (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506425000095/tak-20250331.htm#4220337 Filing: 000139506425000095 The citation records this snapshot. The page link may show a newer release later.	JPY 836.5 billion Calculation and evidence 977156000000 − 140657000000 JPY Exact free cash flow: 836499000000 JPY 2022-04-01 – 2023-03-31: 977156000000 JPY · Inspect Operating Cash Flow · Source 2022-04-01 – 2023-03-31: 140657000000 JPY · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TAKEDA PHARMACEUTICAL CO LTD · 2023-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Free cash flow: 836499000000 JPY Concept: free-cash-flow Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 977156000000 JPY (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506425000095/tak-20250331.htm#4213204 Filing: 000139506425000095 Input fundies:CapitalExpenditure: 140657000000 JPY (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506425000095/tak-20250331.htm#4220337 Filing: 000139506425000095 The citation records this snapshot. The page link may show a newer release later.
2024 2023-04-01 – 2024-03-31	JPY 144.07 billion Exact value Exact value: 144067000000 JPY 2023-04-01 – 2024-03-31: 144067000000 JPY Inspect Net Income Open source Share or cite Citation for Net Income · TAKEDA PHARMACEUTICAL CO LTD · 2024-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Net Income: 144067000000 JPY Concept: fundies:NetIncome Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ANetIncome&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=JPY&dimensions= Input fundies:NetIncome: 144067000000 JPY (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#3629668 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.	JPY 716.34 billion Exact value Exact value: 716344000000 JPY 2023-04-01 – 2024-03-31: 716344000000 JPY Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TAKEDA PHARMACEUTICAL CO LTD · 2024-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Operating Cash Flow: 716344000000 JPY Concept: fundies:OperatingCashFlow Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3AOperatingCashFlow&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=JPY&dimensions= Input fundies:OperatingCashFlow: 716344000000 JPY (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4155165 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.	JPY 175.42 billion Exact value Exact value: 175420000000 JPY 2023-04-01 – 2024-03-31: 175420000000 JPY Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TAKEDA PHARMACEUTICAL CO LTD · 2024-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Capital Expenditure: 175420000000 JPY Concept: fundies:CapitalExpenditure Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ACapitalExpenditure&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=JPY&dimensions= Input fundies:CapitalExpenditure: 175420000000 JPY (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4162197 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.	JPY 540.92 billion Calculation and evidence 716344000000 − 175420000000 JPY Exact free cash flow: 540924000000 JPY 2023-04-01 – 2024-03-31: 716344000000 JPY · Inspect Operating Cash Flow · Source 2023-04-01 – 2024-03-31: 175420000000 JPY · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TAKEDA PHARMACEUTICAL CO LTD · 2024-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Free cash flow: 540924000000 JPY Concept: free-cash-flow Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 716344000000 JPY (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4155165 Filing: 000139506426000177 Input fundies:CapitalExpenditure: 175420000000 JPY (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4162197 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.
2025 2024-04-01 – 2025-03-31	JPY 107.93 billion Exact value Exact value: 107928000000 JPY 2024-04-01 – 2025-03-31: 107928000000 JPY Inspect Net Income Open source Share or cite Citation for Net Income · TAKEDA PHARMACEUTICAL CO LTD · 2025-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Net Income: 107928000000 JPY Concept: fundies:NetIncome Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ANetIncome&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=JPY&dimensions= Input fundies:NetIncome: 107928000000 JPY (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#3630462 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.	JPY 1.06 trillion Exact value Exact value: 1057182000000 JPY 2024-04-01 – 2025-03-31: 1057182000000 JPY Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TAKEDA PHARMACEUTICAL CO LTD · 2025-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Operating Cash Flow: 1057182000000 JPY Concept: fundies:OperatingCashFlow Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3AOperatingCashFlow&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=JPY&dimensions= Input fundies:OperatingCashFlow: 1057182000000 JPY (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4155814 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.	JPY 200.8 billion Exact value Exact value: 200795000000 JPY 2024-04-01 – 2025-03-31: 200795000000 JPY Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TAKEDA PHARMACEUTICAL CO LTD · 2025-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Capital Expenditure: 200795000000 JPY Concept: fundies:CapitalExpenditure Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ACapitalExpenditure&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=JPY&dimensions= Input fundies:CapitalExpenditure: 200795000000 JPY (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4162812 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.	JPY 856.39 billion Calculation and evidence 1057182000000 − 200795000000 JPY Exact free cash flow: 856387000000 JPY 2024-04-01 – 2025-03-31: 1057182000000 JPY · Inspect Operating Cash Flow · Source 2024-04-01 – 2025-03-31: 200795000000 JPY · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TAKEDA PHARMACEUTICAL CO LTD · 2025-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Free cash flow: 856387000000 JPY Concept: free-cash-flow Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1057182000000 JPY (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4155814 Filing: 000139506426000177 Input fundies:CapitalExpenditure: 200795000000 JPY (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4162812 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.
2026 2025-04-01 – 2026-03-31	−JPY 152.39 billion Exact value Exact value: -152390000000 JPY 2025-04-01 – 2026-03-31: -152390000000 JPY Inspect Net Income Open source Share or cite Citation for Net Income · TAKEDA PHARMACEUTICAL CO LTD · 2026-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Net Income: -152390000000 JPY Concept: fundies:NetIncome Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ANetIncome&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=JPY&dimensions= Input fundies:NetIncome: -152390000000 JPY (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#3631257 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.	JPY 1.04 trillion Exact value Exact value: 1041431000000 JPY 2025-04-01 – 2026-03-31: 1041431000000 JPY Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TAKEDA PHARMACEUTICAL CO LTD · 2026-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Operating Cash Flow: 1041431000000 JPY Concept: fundies:OperatingCashFlow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3AOperatingCashFlow&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=JPY&dimensions= Input fundies:OperatingCashFlow: 1041431000000 JPY (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4156465 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.	JPY 176 billion Exact value Exact value: 176003000000 JPY 2025-04-01 – 2026-03-31: 176003000000 JPY Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TAKEDA PHARMACEUTICAL CO LTD · 2026-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Capital Expenditure: 176003000000 JPY Concept: fundies:CapitalExpenditure Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064/explain?concept=fundies%3ACapitalExpenditure&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=JPY&dimensions= Input fundies:CapitalExpenditure: 176003000000 JPY (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4163427 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.	JPY 865.43 billion Calculation and evidence 1041431000000 − 176003000000 JPY Exact free cash flow: 865428000000 JPY 2025-04-01 – 2026-03-31: 1041431000000 JPY · Inspect Operating Cash Flow · Source 2025-04-01 – 2026-03-31: 176003000000 JPY · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TAKEDA PHARMACEUTICAL CO LTD · 2026-03-31 TAKEDA PHARMACEUTICAL CO LTD (edgar:1395064) Free cash flow: 865428000000 JPY Concept: free-cash-flow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T17:59:15Z Snapshot: dce2cf21e659b54577d0f202c170da59eb4f54a99db20c08f33d2900389996aa Dimensions: Consolidated View: https://fundies.io/companies/edgar/1395064?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1041431000000 JPY (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4156465 Filing: 000139506426000177 Input fundies:CapitalExpenditure: 176003000000 JPY (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm#4163427 Filing: 000139506426000177 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

351 filings · 995 latest values · 995 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001395064, 1395064, TAK, TKPHF, edgar:1395064

Also known as TAKEDA PHARMACEUTICAL CO LTD, Takeda Pharmaceutical Company Limited

TAKEDA PHARMACEUTICAL CO LTD

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2026 2025-04-01 – 2026-03-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation